Drwiega, Emily N.
Rodvold, Keith A. http://orcid.org/0000-0002-7200-7346
Article History
Accepted: 18 July 2021
First Online: 15 October 2021
Declarations
:
: This manuscript was not funded in whole or in part by any research grant or funding body.
: Emily Drwiega has no conflicts of interest that are directly relevant to the content of this review. Keith Rodvold has conducted research and/or served as a consultant for intrapulmonary studies discussed in this manuscript for Cempra Pharmaceuticals, Cubist Pharmaceuticals, Durata Therapeutics, Entasis Therapeutics, GlaxoSmithKline, Ortho-McNeil, Paretek Pharmaceuticals, Shionogi & Co., The Medicine Company/Rempex, and Wockhardt Ltd. He has also served on advisory boards, speaking bureaus, or as a consultant for Merck Inc., Shionogi & Co., Sinovent, Spero Therapeutics, The Medicine Company/Qpex Biopharma, and Venatorx Pharmaceuticals.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Both authors made substantial contributions to the conception, drafting, and critical revision of the manuscript for important intellectual content. Both authors approved the final version of the manuscript.
Free to read: This content has been made available to all.